

Open access • Posted Content • DOI:10.1101/2020.10.09.333278

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2 — Source link \square

Romain Gasser, Marc Cloutier, Jérémie Prévost, Corby Fink ...+20 more authors

Institutions: Université de Montréal, Héma-Québec, Robarts Research Institute, University of Western Ontario ...+2 more institutions

Published on: 09 Oct 2020 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Immunoglobulin M, Immunoglobulin G, Immunoglobulin A and Antibody

Related papers:

- Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
- SARS-CoV-2-specific immune response in COVID-19 convalescent individuals.
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
- Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
- Persistence of Functional Memory B Cells Recognizing SARS-CoV-2 Variants Despite Loss of Specific IgG (preprint)



Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2 Romain Gasser^{1,2,10}, Marc Cloutier^{3,10}, Jérémie Prévost^{1,2}, Corby Fink^{4,5}, Éric Ducas³, Shilei Ding¹, Nathalie Dussault³, Patricia Landry³, Tony Tremblay³, Audrey Laforce-Lavoie³, Antoine Lewin^{6,7}, Guillaume Beaudoin-Bussières^{1,2}, Annemarie Laumaea^{1,2}, Halima Medjahed¹, Catherine Larochelle^{1,2,8}, Jonathan Richard^{1,2}, Gregory A. Dekaban^{4,5}, Jimmy D. Dikeakos⁵, Renée Bazin^{3,*}, Andrés Finzi^{1,2,9,*} ¹ Centre de recherche du CHUM, Montréal, OC H2X 0A9, Canada ² Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada ³ Héma-Québec, Affaires Médicales et Innovation, Québec, QC G1V 5C3, Canada ⁴ Biotherapeutics Research Laboratory, Robarts Research Institute, London, Ontario, NGA 5B7. Canada ⁵ Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, N6A 5B7, Canada ⁶ Héma-Ouébec, Affaires Médicales et Innovation, Montréal, OC H4R 2W7, Canada ⁷ Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada ⁸ Department of Neurosciences, University of Montreal, Montreal, QC H2X 0A9, Canada ⁹ Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada ¹⁰ These authors contributed equally * Correspondence: renee.bazin@hema-quebec.qc.ca; andres.finzi@umontreal.ca Running Title: Major role of IgM in SARS-CoV-2 neutralization Keywords: COVID-19, SARS-CoV-2, Spike glycoprotein, IgM, IgA, IgG, neutralization, convalescent plasma

45 Abstract

Characterization of the humoral response to SARS-CoV-2, the etiological agent of Covid-19, 46 is essential to help control the infection. In this regard, we and others recently reported that the 47 neutralization activity of plasma from COVID-19 patients decreases rapidly during the first 48 weeks after recovery. However, the specific role of each immunoglobulin isotype in the overall 49 neutralizing capacity is still not well understood. In this study, we selected plasma from a cohort 50 of Covid-19 convalescent patients and selectively depleted immunoglobulin A, M or G before 51 52 testing the remaining neutralizing capacity of the depleted plasma. We found that depletion of immunoglobulin M was associated with the most substantial loss of virus neutralization, 53 followed by immunoglobulin G. This observation may help design efficient antibody-based 54 COVID-19 therapies and may also explain the increased susceptibility to SARS-CoV-2 of 55 autoimmune patients receiving therapies that impair the production of IgM. 56

58 Introduction

59

Since its discovery in Wuhan in 2019, the causative agent of COVID-19, the SARS-CoV-2 60 61 virus (Zhu et al., 2020), has become a major global public health problem. A better understanding of immune responses induced by SARS-CoV-2 is urgently needed to help control 62 the infection. Several studies have shown that the neutralization activity of plasma from 63 COVID-19 patients decreases rapidly during the first weeks after recovery (Beaudoin-Bussières 64 et al., 2020; Long et al., 2020; Prévost et al., 2020; Robbiani et al., 2020; Seow et al., 2020). 65 Although a good correlation between the presence of Spike (S)-specific antibodies and the 66 67 capacity of plasma from infected individuals to neutralize viral particles was reported, recent data looking at individual immunoglobulin (Ig) isotypes revealed a stronger correlation between 68 the decrease in S-specific IgM antibodies and loss of neutralization compared to S-specific IgG 69 and IgA antibodies, suggesting that IgM play an important role in the neutralization activity of 70 plasma from individuals who suffered from COVID-19 (Beaudoin-Bussières et al., 2020; 71 72 Prévost et al., 2020). To better understand the relative contribution of S-specific IgM, IgA and 73 IgG antibodies in SARS-CoV-2 neutralization, we selectively depleted each Ig isotype from plasma obtained from 25 convalescent donors and assessed the impact of depletion on the 74 75 capacity of the plasma to neutralize SARS-CoV-2 pseudoviral particles and wild type infectious 76 SARS-CoV-2 viral particles.

- 77
- 78 **Results**

79

```
80 Ig depletion
```

Demographic information of the 25 convalescent donors (21 males, 4 females, median = 45
days after symptoms onset), who were diagnosed with or tested positive for SARS-CoV-2 with

complete resolution of symptoms for at least 14 days before sampling are presented in Table 1. 83 Selective depletion of IgM, IgA or IgG was achieved by adsorption on isotype-specific ligands 84 immobilized on Sepharose or agarose beads, starting with a five-fold dilution of plasma (see 85 86 details in Stars Methods). The depletion protocols permitted to efficiently deplete each isotype while leaving the other isotypes nearly untouched, as measured by ELISA (Fig 1A-C). 87 Depletion of IgG had a much higher impact on the total level of SARS-CoV-2 RBD antibodies 88 89 than IgM and IgA depletion (Fig 1D), although RBD-specific antibodies of each isotype were selectively removed by the depletion (Fig. 1E-G). The impact of IgG depletion on the level of 90 total antibodies against the full S glycoprotein expressed on 293T cells (measured by flow 91 cytometry) was also noticeable (Fig. 1H) whereas isotype-specific detection of full S antibodies 92 by flow cytometry confirmed the efficacy of selective depletion (Fig. 1I-K). 93

94

95 Neutralizing activity of depleted plasma

We then evaluated the capacity of non-depleted and isotype-depleted plasma samples to 96 97 neutralize pseudoviral particles expressing the S glycoprotein from SARS-CoV-2 (Prévost et 98 al., 2020) (Star Methods). Depletion of IgM, IgA or IgG all resulted in a significant decrease of neutralization compared to non-depleted plasma (Fig. 2A-D). However, the loss of 99 100 neutralization activity was much more pronounced in IgM- and IgG-depleted plasma with a 5.5 101 and 4.5 fold decrease in mean ID_{50} compared to non-depleted plasma respectively, than in IgAdepleted plasma where a 2.4 fold decrease only was observed (Fig. 2E). To evaluate whether 102 the impact of isotype depletion on neutralization could be extended beyond pseudoviral 103 104 particles, we tested plasma from eight donors in microneutralization experiments using fully infectious SARS-CoV-2 viral particles, as described in the Star Methods. The neutralizing 105 106 potency of plasma was greatly reduced following IgM and IgG (4.0 and 2.9 fold respectively) but not IgA (no decrease) depletion (Fig. 2F and G). Despite the limited number of samples 107

tested with the live virus, the impact of IgM and IgG depletion on neutralization was similar to
that observed with the same samples in the pseudoviral particles neutralization assay (Fig. 3AC). This data not only confirms the role of IgG in neutralizing activity of convalescent plasma
but also highlights the important contribution of IgM with respect to neutralization activity.

112

113 **Discussion**

114

115 Our findings detailing the important role of IgM in the neutralizing activity of convalescent plasma has several implications. First, although the therapeutic efficacy of convalescent plasma 116 117 for the treatment of COVID-19 patients remains to be established, it is likely that neutralizing antibodies will play a role. Because SARS-CoV-2 specific IgM antibodies rapidly decrease 118 after disease onset (Beaudoin-Bussières et al., 2020; Prévost et al., 2020; Robbiani et al., 2020; 119 120 Seow et al., 2020), the collection of convalescent plasma with maximal neutralizing activity should be performed early after disease recovery. Second, our results suggest that caution 121 122 should be taken when using therapeutics that impair the production of IgM. Anti-CD20 123 antibodies (B cell-depleting agents) are used to treat several inflammatory disorders. Their use is associated with IgM deficiency in a substantial number of patients, while their impact on IgG 124 and IgA levels is more limited (Kridin and Ahmed, 2020). In line with our data, recent studies 125 126 reported that anti-CD20 therapy could be associated with a higher susceptibility to contract SARS-CoV-2 and develop severe COVID-19 (Guilpain et al., 2020; Hughes et al., 2020; Safavi 127 et al., 2020; Schulze-Koops et al., 2020; Sharmeen et al., 2020; Sormani et al., 2020). Whether 128 129 this is associated to the preferential depletion of IgM-producing B cells by these treatments (Looney et al., 2008) remains to be shown. Nevertheless, our results suggest that IgM levels 130 should be investigated as a biomarker to stratify patients on immunosuppressive therapies at 131 higher risk for COVID-19. 132

In summary, our results extend previous observations showing a strong correlation between 133 neutralization potency and the presence of RBD-specific IgM (Beaudoin-Bussières et al., 2020; 134 Perera et al., 2020; Prévost et al., 2020; Seow et al., 2020). It is intriguing that IgM represents 135 about only 5% of the total antibodies in plasma (Wang et al., 2020), yet plays such an important 136 role in SARS-CoV-2 neutralization. Whether this is due to the enhanced avidity provided by its 137 pentameric nature remains to be formally demonstrated but is in agreement with recent work 138 demonstrating that dimeric antibodies are more potent than their monomeric counterpart (Wang 139 140 et al., 2020). The possible establishment of long lived IgM-producing B cells that might contribute to long term immunity of recovered patients has been suggested (Brouwer et al., 141 2020; Newell et al., 2020). However, how plasma neutralization evolves over prolonged periods 142 of time and the specific role of IgM in this activity remains to be determined. 143

144

145 Acknowledgments

This work was supported by "Ministère de l'Économie et de l'Innovation du Québec, 146 147 Programme de soutien aux organismes de recherche et d'innovation", by the Fondation du 148 CHUM, by the Canada's COVID-19 Immunity Task Force (CITF), in collaboration with the Canadian Institutes of Health Research (CIHR) and a CIHR foundation grant #352417 to A.F. 149 Funding was also provided by an operating grant from CIHR from the Canadian 2019 Novel 150 151 Coronavirus (COVID-19) Rapid Research Funding Opportunity (FRN440388 to JDD and GAD) and an Infrastructure Grant from CFI for the Imaging Pathogens for Knowledge 152 Translation (ImPaKT) Facility (#36287 to JDD and GAD). A.F. is the recipient of a Canada 153 Research Chair on Retroviral Entry # RCHS0235 950-232424. R.G. is supported by a MITACS 154 Accélération postdoctoral fellowship. J.P. is supported by a CIHR graduate fellowship. 155

156

158 Author Contributions

- 159 R.G., M.C., J.P., R.B. and A.F. designed the studies. R.G. and S.D. performed neutralization
- 160 experiments with pseudoviral particles. J.P. performed flow cytometry experiments. C.F.,
- 161 G.A.D. and J.D.D. performed microneutralization assays with infectious wildtype SARS-CoV-
- 162 2 and analysed the results. M.C., E.D., N.D., P.L., A.L.L. and T.T. depleted plasma samples
- and performed the ELISA. J.R. provided new reagents. A.L. performed statistical analysis. C.L.
- 164 provided scientific and clinical input. R.G., M.C., R.B. and A.F. wrote the manuscript with
- 165 inputs from others. Every author has read, edited and approved the final manuscript.
- 166

167 **Competing interests**

- 168 The authors declare no-competing interests
- 169
- 170
- 171

172 Figure Legends

173

174 Figure 1. IgM, IgA and IgG depletion in plasma samples from convalescent donors.

(A-C) Efficacy of the specific isotype depletion assessed by ELISA for total IgM, IgA and IgG. 175 All plasma samples were diluted 5-fold prior to depletion; (A) IgM concentration in non-176 depleted, IgM-depleted, IgA-depleted and IgG-depleted plasmas, measured using an anti-177 178 human IgM (µ-chain specific) as capture antibody; (B) IgA concentration measured on the same plasmas using anti-human IgA (α -chain specific); (C) IgG concentration measured using anti-179 human IgG (y-chain specific). (D-G) Efficacy of SARS-CoV-2 specific antibody depletion 180 assessed by SARS-CoV-2 RBD ELISA; (D) Level of total (pan-Ig) anti-SARS-CoV-2 RBD-181 specific antibodies in non-depleted, IgM-depleted, IgA depleted and IgG-depleted plasmas; (E) 182 Level of IgM-specific anti-RBD; (F) Level of IgA-specific anti-RBD; (G) Level of IgG-specific 183 184 anti-RBD. (H-K) Efficacy of full S glycoprotein-specific antibody depletion measured by flow cytometry; (H) Level of total (pan-Ig) anti-SARS-CoV-2 S-specific antibodies in non-depleted, 185 IgM-depleted, IgA-depleted and IgG-depleted plasmas; (I) Level of IgM-specific anti-S; (J) 186 Level of IgA-specific anti-S; (K) Level of IgG-specific anti-S. Asterisks indicate the level of 187 statistical significance obtained by a Dunn's test; **** p<0.0001. 188

189

190 Figure 2. Role of IgM, IgA and IgG in neutralization.

(A) Comparison of the SARS-CoV-2 pseudoviral inhibitory dilution (ID₅₀) of all plasma
samples. (B-D) ID₅₀ of plasma from each convalescent donor before and after (B) IgM, (C) IgA
and (D) IgG depletion. (E) Fold decrease (isotype-depleted versus non-depleted plasma) in ID₅₀
measured by SARS-CoV-2 pseudovirions neutralization. (F-G) Microneutralization assay
using infectious wild type SARS-CoV-2 performed on non-depleted and isotype-depleted
plasma from 3 donors; (F) Mean percentage of infection observed with plasma from the 3

donors and (G) Fold decrease (isotype-depleted versus non-depleted plasma) in ID₅₀ measured
by microneutralization of wild type SARS-CoV-2 virions. Asterisks indicate the level of
statistical significance obtained by a Wilcoxon signed rank test, n.s. not significant; *p<0.05;
p<0.01; *p<0.001; ****p<0.0001.

201

Figure 3. Neutralizing capacity of eight convalescent plasma using pseudoviral particles or microneutralization with infectious wild type SARS-CoV-2 virus.

204 ID_{50} obtained by (A) virus microneutralization assay or (B) pseudoviral particles neutralization assay for non-depleted or isotype-depleted plasma of eight convalescent donors. (C) Spearman 205 correlation and linear regression fitting between the ID₅₀ obtained by microneutralization and 206 207 pseudoviral particles neutralization assays. Dashed lines indicate the 95% confidence interval of the linear regression fitting. Non-depleted plasmas are shown in black, IgM-depleted in blue, 208 209 IgA-depleted in red and IgG-depleted in green. Asterisks indicate the level of statistical significance obtained by a Wilcoxon signed rank test, n.s. not significant; **p<0.01; 210 ****p<0.0001. 211

212

213

214

215

bioRxiv preprint doi: https://doi.org/10.1101/2020.10.09.333278; this version posted October 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

217 Table 1. COVID convalescent plasma donor's characteristics

	All donors	Males	Females
Donors (n)	25	21	4
Average age ± SD [range]	47 ± 16 [20-69]	49 ± 17 [20-69]	40 ± 14 [29-60]
Age (median)	50	51	34.5
Period (days) between symptoms onset and donation (median [range])	45 [25-69]	47 [25-69]	40 [27-56]

218

220 Material and Methods

221

222 Ethics statement

All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate Ethics Review board. Convalescent plasmas were obtained from donors who consented to participate in this research project at CHUM (19.381) and at Héma-Québec (REB # 2020-004). The donors met all donor eligibility criteria: previous confirmed COVID-19 infection and complete resolution of symptoms for at least 14 days.

228

229 Plasmids

The plasmids expressing the human coronavirus Spike of SARS-CoV-2 was kindly provided by Stefan Pöhlmann and was previously reported (Hoffmann et al., 2020). The pNL4.3 R-E-Luc was obtained from NIH AIDS Reagent Program. The codon-optimized RBD sequence (encoding residues 319-541) fused to a C-terminal hexahistidine tag was cloned into the pcDNA3.1(+) expression vector and was reported elsewhere (Beaudoin-Bussières et al., 2020). The vesicular stomatitis virus G (VSV-G)-encoding plasmid (pSVCMV-IN-VSV-G) was previously described (Lodge et al., 1997).

237

238 Cell lines

293T human embryonic kidney cells (obtained from ATCC) and Vero E6 cells (ATCC CRL1586TM) were maintained at 37°C under 5% CO2 in Dulbecco's modified Eagle's medium
(DMEM) (Wisent) containing 5% fetal bovine serum (VWR), 100 UI/ml of penicillin and
100µg/ml of streptomycin (Wisent). The 293T-ACE2 cell line was previously reported (Prévost
et al., 2020). For the generation of 293T cells stably expressing SARS-CoV-2 Spike, VSV-G
pseudotyped lentivirus packaging the SARS-CoV-2 Spike was produced in 293T using a third-

generation lentiviral vector system. Briefly, 293T cells were co-transfected with two packaging
plasmids (pLP1 and pLP2), an envelope plasmid (pSVCMV-IN-VSV-G) and a lentiviral
transfer plasmid coding for a GFP-tagged SARS-CoV-2 Spike (pLV-SARS-CoV-2 S CGFPSpark tag) (SinoBiological). Supernatant containing lentiviral particles was used to infect
293T cells in presence of 5µg/mL polybrene. The 293T cells stably expressing SARS-CoV-2
Spike (GFP+) were sorted by flow cytometry. SARS-CoV-2 expression was confirmed using
the CR3022 mAb and plasma from SARS-CoV-2-infected individuals.

252

Isotype depletion

Selective depletion of IgM, IgA or IgG was done by adsorption on isotype-specific ligands 254 immobilized on sepharose or agarose beads starting with a five-fold dilution of plasma in PBS. 255 IgG and IgA antibodies were depleted from plasma obtained from 25 recovered COVID-19 256 257 patient using Protein G HP Spintrap (GE Healthcare Life Sciences, Buckinghamshire, UK) and 258 Peptide M / Agarose (InvivoGen, San Diego, CA), respectively, according to the 259 manufacturer's instructions with the exception that no elution step for the recovery of the 260 targeted antibodies was done. For IgM depletion, anti-human IgM (µ-chain specific, Sigma, St.Louis, MO) was covalently coupled to NHS HP SpinTrap (GE Healthcare) at 815 µg/mL of 261 matrix. Depletion was performed according to the manufacturer's instructions with the 262 263 exception that no elution step for the recovery of the targeted isotype was done. All nondepleted and isotype-depleted samples were filtered on a 0.22 µm Millex GV filter 264 (SLGV013SL, Millipore, Burlington, MA) to ensure sterility for the virus capture and 265 neutralization assays. 266

267

268

270 Immunoglobulin isotype ELISA

To assess the extent of IgM, IgG and IgA depletion, ELISA were performed on non-depleted 271 272 as well as IgM-, IgA- and IgG-depleted plasma samples. Each well of a 96-well microplate was filled with either goat anti-human IgM (µ-chain specific) at 5 µg/mL, goat anti-human serum 273 274 IgA (α -chain specific) at 0.3 µg/mL or goat anti-human IgG (γ -chain specific) at 5 µg/mL (all from Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Microtiter plates were 275 sealed and stored overnight at 2-8°C. After four (IgA) to six (IgM and IgG) washes with H₂O-276 0.1% Tween 20 (Sigma), 200 µL of blocking solution (10 mmol/L phosphate buffer, pH 7.4, 277 containing 0.85% NaCl, 0.25% Hammerstein casein (EMD Chemicals Inc., Gibbstown, NJ.) 278 were added to each well to block any remaining binding sites. The blocking solution for the 279 IgG and IgM ELISA also contained 0.05% Tween 20. After 0.5 (IgA) to 1h (IgM and IgG) 280 incubation at 37°C and washes, samples and the standard curves (prepared with human 281 calibrated standard serum, Cedarlane, Burlington, Canada) were added to the plates in 282 triplicates. Plates were incubated for 1h at 37°C. After washes, 100 µL of either goat anti-human 283 284 IgA+G+M (H+L) HRP conjugate (1/30 000), goat anti-human IgG (H+L) HRP conjugate (1/30 000) or goat anti-human IgA (a-chain specific) HRP conjugate (1/10 000) (all from 285 Jackson ImmunoResearch Laboratories, Inc.) were added and samples were incubated at 37°C 286 for 1h. Wells were washed and bound antibodies were detected by the addition of 100 µL of 287 3,3',5,5'-tetramethylbenzimidine (TMB, ScyTek Laboratories, Logan, UT). The enzymatic 288 reaction was stopped by the addition of 100 µL 1 N H₂SO₄ and the absorbance was measured 289 at 450/630 nm within 5 minutes. 290

291

292

294 SARS-CoV-2 RBD ELISA

The presence of SARS-CoV-2 RBD-specific antibodies in the plasma from 25 recovered 295 COVID-19 patients before and after depletion was measured using an ELISA adapted from a 296 297 recently described protocol (Beaudoin-Bussières et al., 2020; Perreault et al., 2020; Prévost et al., 2020). The plasmid encoding for SARS-CoV-2 RBD was synthesized commercially 298 (Genscript, Piscataway, NJ, USA). Recombinant RBD proteins were produced in transfected 299 FreeStyle 293F cells (Invitrogen, Carlsbad, CA, USA) and purified by nickel affinity 300 301 chromatography. Recombinant RBD was diluted to 2.5 µg/mL in PBS (Thermo Fisher Scientific, Waltham, MA, USA) and 100 µl of the dilution was distributed in the wells of flat-302 303 bottom 96-well microplates (Immulon 2HB; Thermo Scientific). The plates were placed overnight at 2-8°C for antigen adsorption. For the assay, the plates were emptied and a volume 304 of 300 µl/well of blocking buffer (PBS-0.1% Tween (Sigma)-2% BSA (Sigma)) was added. 305 306 The microplates were incubated for one hour at room temperature (RT) followed by washing 307 four times (ELx405 microplate washer, Bio-Tek) with 300 µL/well of washing solution (PBS-308 0.1% Tween). Because the reaction is time sensitive, samples, negative and positive controls 309 were prepared in triplicates in a plate, then transferred in the RBD coated plate by reverse multipipetting. The negative control was prepared from a pool of 23 COVID negative plasmas while 310 311 the positive control was a characterized plasma from a recovered patient. After transfer, the plates were incubated for 60 minutes at 20-24°C. After four washes, 100 µL of either goat anti-312 human IgA+G+M (H+L) HRP conjugate (1/30 000) for the detection of all isotypes, goat anti-313 human IgM (µ-chain specific) HRP conjugate (1/15 000), F(ab')₂ fragment goat anti-human 314 IgA (α-chain specific) HRP conjugate (1/4500) (all from Jackson Immunosearch Laboratories, 315 316 Inc.) or goat anti-human IgG (γ -chain specific) HRP conjugate (1/50 000) (Invitrogen) were added and samples were incubated at 20-24°C for 60 minutes. Wells were washed four times 317 and bound antibodies were detected by the addition of 100 µL of 3,3',5,5'-318

tetramethylbenzimidine (ScyTek Laboratories). The enzymatic reaction was stopped by the addition of 100 μ L 1 N H₂SO₄ and the absorbance was measured at 450/630 nm within 5 minutes.

322

323 Flow cytometry analysis of cell-surface staining

293T cells stably expressing SARS-CoV-2 Spike with a C-GFP tag (293T-Spike) were mixed 324 at a 1:1 ratio with non-transduced 293T cells and were stained with plasma from SARS-CoV-325 326 2-infected individuals (1:250 dilution). Plasma binding to cell-surface Spike was revealed using fluorescent secondary antibodies able to detect all Ig isotypes (anti-human IgM+IgG+IgA; 327 Jackson ImmunoResearch Laboratories, Inc.) or specific to IgG isotype (Biolegend), IgM 328 isotype (Jackson ImmunoResearch Laboratories, Inc.) or IgA isotype (Jackson 329 ImmunoResearch Laboratories, Inc.). The living cell population was gated on the basis of a 330 331 viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSRII cytometer (BD Biosciences, Mississauga, ON, Canada) and data analysis was performed using FlowJo 332 333 v10.5.3 (Tree Star, Ashland, OR). The signal obtained with 293T (GFP- population) was subtracted from the signal obtained with 293T-Spike (GFP+ population) to remove unspecific 334 signal. 335

336

337 Neutralization assay using pseudoviral particles

Target cells were infected with single-round luciferase-expressing lentiviral particles as described previously (Prévost et al., 2020). Briefly, 293T cells were transfected by the calcium phosphate method with the lentiviral vector pNL4.3 R-E- Luc (NIH AIDS Reagent Program) and a plasmid encoding for SARS-CoV-2 Spike at a ratio of 5:4. Two days post-transfection, cell supernatants were harvested and stored at -80° C until use. 293T-ACE2 target cells were seeded at a density of 1×10^4 cells/well in 96-well luminometer-compatible tissue culture plates

(Perkin Elmer) 24h before infection. Recombinant viruses in a final volume of 100µl were 344 incubated with the indicated plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31 250) for 1h at 345 37°C and were then added to the target cells followed by incubation for 48h at 37°C; cells were 346 lysed by the addition of 30µl of passive lysis buffer (Promega) followed by one freeze-thaw 347 cycle. An LB941 TriStar luminometer (Berthold Technologies) was used to measure the 348 luciferase activity of each well after the addition of 100µl of luciferin buffer (15mM MgSO₄, 349 15mM KPO₄ [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50µl of 1mM d-luciferin 350 potassium salt (Prolume). The neutralization half-maximal inhibitory dilution (ID₅₀) represents 351 the sera dilution to inhibit 50% of the infection of 293T-ACE2 cells by recombinant viruses. 352

353

354 Microneutralization assay using live SARS-CoV-2 viral particles

A microneutralization assay for SARS-CoV-2 serology was performed as previously described 355 356 (Amanat et al., 2020). The assay was conducted with the person blinded to the sample identity. Experiments were conducted with the SARS-CoV-2 USA-WA1/2020 virus strain. This reagent 357 358 was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. 359 One day prior to infection, $2x10^4$ Vero E6 cells were seeded per well of a 96 well flat bottom 360 plate and incubated overnight (37°C/5% CO₂) to permit Vero E6 cell adherence. On the day of 361 362 infection, all plasma samples were heat inactivated at 56°C for one hour. Non-depleted plasma from each donor was also included in this assay. Plasma dilutions were performed in a separate 363 96 well culture plate using MEM supplemented with penicillin (100 U/mL), streptomycin (100 364 365 µg/mL), HEPES, L-Glutamine (0.3 mg/mL), 0.12% sodium bicarbonate, 2% FBS (all from Thermo Fisher Scientific) and 0.24% BSA (EMD Millipore Corporation). Plasma dilutions 366 367 ranged from 1:50 to 1:31 250. In a Biosafety Level 3 laboratory (ImPaKT Facility, Western University), 10³ TCID₅₀/mL SARS-CoV-2 USA-WA1/2020 virus strain was prepared in MEM 368

+ 2% FBS and combined with an equivalent volume of respective plasma dilution for one hour 369 at room temperature. After this incubation, all media was removed from the 96 well plate seeded 370 with Vero E6 cells and virus:plasma mixtures were added to each respective well at a volume 371 372 corresponding to 600 TCID₅₀ per well and incubated for one hour further at 37°C. Both virus only and media only (MEM + 2% FBS) conditions were included in this assay. All virus:plasma 373 supernatants were removed from wells without disrupting the Vero E6 monolayer. Each plasma 374 dilution (100 µL) was added to its respective Vero E6-seeded well in addition to an equivalent 375 376 volume of MEM + 2% FBS and was then incubated for 48 hours. Media was then discarded and replaced with 10% formaldehyde for 24 hours to cross-link Vero E6 monolayer. 377 378 Formaldehyde was removed from wells and subsequently washed with PBS. Cell monolayers were permeabilized for 15 minutes at room temperature with PBS + 0.1% Triton X-100 (BDH 379 Laboratory Reagents), washed with PBS and then incubated for one hour at room temperature 380 381 with PBS + 3% non-fat milk. An anti-mouse SARS-CoV-2 nucleocapsid protein (Clone 1C7, Bioss Antibodies) primary antibody solution was prepared at 1 µg/mL in PBS + 1% non-fat 382 383 milk and added to all wells for one hour at room temperature. Following extensive washing 384 with PBS, an anti-mouse IgG HRP secondary antibody solution was formulated in PBS + 1% non-fat milk. One hour post-room temperature incubation, wells were washed with PBS, 385 SIGMAFASTTM OPD developing solution (Millipore Sigma) was prepared as per 386 387 manufacturer's instructions and added to each well for 12 minutes. Dilute HCl (3.0 M) was added to quench the reaction and the optical density at 490 nm of the culture plates was 388 immediately measured using a Synergy LX multi-mode reader and Gen5[™] microplate reader 389 390 and imager software (BioTek®).

391

392

394 Statistical analysis

Statistics were analyzed using GraphPad Prism version 8.0.2 (GraphPad, San Diego, CA,
(USA). Every data set was tested for statistical normality and this information was used to apply
the appropriate (parametric or nonparametric) statistical test. P values <0.05 were considered
significant; significance values are indicated as *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001.

- 402
- 403

404 **References**

405 Amanat, F., White, K.M., Miorin, L., Strohmeier, S., McMahon, M., Meade, P., Liu, W.-C.,

Albrecht, R.A., Simon, V., Martinez-Sobrido, L., et al. (2020). An In Vitro Microneutralization
 Assay for SARS-CoV-2 Serology and Drug Screening. Curr. Protoc. Microbiol. 58, e108.

Beaudoin-Bussières, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,
Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of humoral
responses against SARS-CoV-2 Spike in convalescent individuals. BioRxiv
2020.07.09.194639. mBio in press

- 412 Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S.,
- 413 Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing
- antibodies from COVID-19 patients define multiple targets of vulnerability. Science.
- Guilpain, P., Le Bihan, C., Foulongne, V., Taourel, P., Pansu, N., Maria, A.T.J., Jung, B.,
 Larcher, R., Klouche, K., and Le Moing, V. (2020). Rituximab for granulomatosis with
 polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann.
- 418 Rheum. Dis.
- 419 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S.,
- Schiergens, T.S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry
 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
 Cell *181*, 271-280.e8.
- Hughes, R., Pedotti, R., and Koendgen, H. (2020). COVID-19 in persons with multiple sclerosis
 treated with ocrelizumab A pharmacovigilance case series. Mult. Scler. Relat. Disord. 42,
 102192.
- 426 Kridin, K., and Ahmed, A.R. (2020). Post-rituximab immunoglobulin M (IgM)
 427 hypogammaglobulinemia. Autoimmun. Rev. 19, 102466.
- Lodge, R., Lalonde, J.P., Lemay, G., and Cohen, E.A. (1997). The membrane-proximal
 intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral
 targeting of viral budding in MDCK cells. EMBO J. *16*, 695–705.
- Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang,
 Y., Lv, F.-J., et al. (2020). Clinical and immunological assessment of asymptomatic SARSCoV-2 infections. Nat. Med. *26*, 1200–1204.
- Looney, R.J., Srinivasan, R., and Calabrese, L.H. (2008). The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum. *58*, 5–14.
- Newell, K.L., Clemmer, D.C., Cox, J.B., Kayode, Y.I., Zoccoli-Rodriguez, V., Taylor, H.E.,
 Endy, T.P., Wilmore, J.R., and Winslow, G. (2020). Switched and unswitched memory B cells
 detected during SARS-CoV-2 convalescence correlate with limited symptom duration.
 MedRxiv 2020.09.04.20187724.
- Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C., Yuan, M., Leung, W.S.,
 Chan, J.M., Chik, T.S., et al. (2020). Serological assays for severe acute respiratory syndrome
 coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance 25, 2000421.

- 443 Perreault, J., Tremblay, T., Fournier, M.-J., Drouin, M., Beaudoin-Bussières, G., Prévost, J.,
- Lewin, A., Bégin, P., Finzi, A., and Bazin, R. (2020). Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within four months after symptom onset. Blood.
- Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand,
 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-sectional evaluation of humoral
 responses against SARS-CoV-2 Spike. Cell Rep. Med. 100126.
- Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M.,
 Barnes, C.O., Gazumyan, A., Finkin, S., et al. (2020). Convergent antibody responses to SARS-
- 450 Barnes, C.O., Gazuniyan, A., Finkin, S., et al. (2020). Convergent antibody respondence of the convergence of the convergen
- 451 CoV-2 in convalescent individuals. Nature *584*, 437–442.
- 452 Safavi, F., Nourbakhsh, B., and Azimi, A.R. (2020). B-cell depleting therapies may affect
 453 susceptibility to acute respiratory illness among patients with multiple sclerosis during the early
 454 COVID-19 epidemic in Iran. Mult. Scler. Relat. Disord. *43*, 102195.
- 455 Schulze-Koops, H., Krueger, K., Vallbracht, I., Hasseli, R., and Skapenko, A. (2020). Increased 456 risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with
- 457 rituximab. Ann. Rheum. Dis.
- 458 Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K.J.A., Hemmings, O., O'Bryne, A.,
- Kouphou, N., Pickering, S., Galao, R., et al. (2020). Longitudinal evaluation and decline of
 antibody responses in SARS-CoV-2 infection. MedRxiv 2020.07.09.20148429.
- antibody responses in SARS-CoV-2 infection. MedRxiv 2020.07.09.20148429.
- Sharmeen, S., Elghawy, A., Zarlasht, F., and Yao, Q. (2020). COVID-19 in rheumatic disease
 patients on immunosuppressive agents. Semin. Arthritis Rheum. *50*, 680–686.
- Sormani, M.P., De Rossi, N., Schiavetti, I., Carmisciano, L., Cordioli, C., Moiola, L., Radaelli,
 M., Immovilli, P., Capobianco, M., Trojano, M., et al. (2020). Disease Modifying Therapies
 and COVID-19 Severity in Multiple Sclerosis (Rochester, NY: Social Science Research
 Network).
- Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M.,
 Hoffman, H.-H., Oliveira, T.Y., Oren, D.A., et al. (2020). Enhanced SARS-CoV-2
 Neutralization by Secretory IgA in vitro. BioRxiv 2020.09.09.288555.
- 470 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R.,
- et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J.
- 472 Med.






Figure 2

